Northwest Biotherapeutics (NWBO) Cash & Equivalents (2010 - 2026)

Northwest Biotherapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 35.73% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 35.73% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, up 39.77% from the prior year.
• Cash & Equivalents fell to $1.8 million in Q1 2026 per NWBO's latest filing, from $3.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.4 million in Q3 2022 and bottomed at $1.4 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $3.0 million (2025), against an average of $4.2 million.
• Across the five-year window, Cash & Equivalents surged 145.7% in 2022 and slumped 70.52% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $7.0 million in 2022, then slumped by 69.48% to $2.1 million in 2023, then rose by 2.3% to $2.2 million in 2024, then surged by 39.77% to $3.0 million in 2025, then tumbled by 41.25% to $1.8 million in 2026.
• Per Business Quant, the three latest NWBO Cash & Equivalents figures stand at $1.8 million (Q1 2026), $3.0 million (Q4 2025), and $4.6 million (Q3 2025).